openPR Logo
Press release

Bristol-Meyers Squibb Sued by 72 Plaintiffs Over Plavix Side Effects

01-30-2012 05:00 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen LLP

Nadrick & Cohen, LLP reports that 72 plaintiffs have joined together in a Plavix side effects lawsuit filed against Bristol-Meyers Squibb.

Los Angeles, CA, January 27, 2012 – Seventy-two plaintiffs from across the country have joined together in filing a Plavix side effects lawsuit against the drug’s maker, Bristol-Meyers Squibb. According to the Madison Record, the plaintiffs are seeking an unspecified amount of compensation for injuries they say were caused by the drug.

The lawsuit, filed in an Illinois circuit court, includes plaintiffs from a number of states, including Ohio, California, Louisiana, New York and Connecticut. The plaintiffs allege that Plavix caused heart attacks, strokes, internal bleeding and other serious complications. The lawsuit also claims that Bristol-Meyers and co-defendant Sanofi Aventis marketed the drug inappropriately and failed to adequately warn consumers of the potential dangers.

Plavix (clopidogrel) was first approved by the U.S. Food and Drug Administration in 1997 for the prevention of heart attack and stroke. The drug was touted as being more effective and safer in reducing the risk of cardiovascular complications compared to a daily aspirin regimen.

In 2010, the FDA issued a new black box warning label for Plavix, advising health care professionals and patients that the drug’s effectiveness may be reduced for patients with a specific genetic variant. A new study published in 2011 suggested that the genetic test may not be as significant as previously thought in determining the drug’s effectiveness.

Patients who experienced complications after taking Plavix are urged to complete a MedWatch form by visiting the Food and Drug Administration’s website. It is also recommended that you contact an experienced personal injury lawyer to discuss your rights.

Nadrich & Cohen LLP offers confidential, no-cost consultations to Plavix users who believe they were harmed by the drug. Help is available by calling the firm’s injury hotline at 1-800-722-0765 or by completing an online case evaluation form at www.personalinjurylawcal.com.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling Plavix side effects claims, Nadrich & Cohen, LLP investigates cases involving Accutane, Avandia, DePuy Hip Implants, Zimmer Hips, Wright Conserve Hips, Vaginal Mesh, Pradaxa, Stevens-Johnson Syndrome, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. All cases are accepted on a contingency basis, meaning there is never a fee unless we recover a judgment on your behalf. The time you have to file an injury claim is limited, so it’s important that you act quickly to protect your rights.

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bristol-Meyers Squibb Sued by 72 Plaintiffs Over Plavix Side Effects here

News-ID: 208823 • Views:

More Releases from Nadrich & Cohen LLP

Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country. Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the

All 5 Releases


More Releases for Plavix

Clopidogrel Bisulfate Market 2021: Global Industry Analysis Report to 2027
The global clopidogrel bisulfate market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Clopidogrel bisulfate is used for the treatment of serious or life-threatening problems with the heart and blood vessels. It is given to people who have had a stroke, heart attack, or severe chest pain. The major factor for the growth of the market during the forecast period is the increasing demand for
Global Clopidogrel Bisulfate Market, Growth Analysis, Latest Trends and Forecast …
Clopidogrel, often known as Plavix, is an antiplatelet medicine used to lower the risk of heart disease and stroke in people who are at high risk. It is also used in conjunction with aspirin in the treatment of heart attacks and after the implantation of a coronary artery stent (dual antiplatelet therapy). It is administered orally. The effects begin to appear after around two hours and remain for five days.
Ephedrine Market expected to get Huge Growth in Forecast Year 2020-2025| Sanofi, …
The Ephedrine market 2020 report analyses global acceptance of trends, future growth potential, key drivers, limitations, opportunities, and best practices that are taken place in market. The report also examines growth potential, market sizes and revenue forecasts (2020-2025)across different regions as well as industry verticals. Global Ephedrine Market Overview: Ephedrine is a decongestant and bronchodilator, used to treat bronchospasms caused owing to asthma. The medicine decreases the puffiness and constricts the blood
Cardiovascular disease market set to grow very slowly to $146.4 billion by 2022
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%. Thomas Jarratt, Associate Analyst for GBI Research, explains: “Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi’s Praluent (alirocumab) is expected to help mitigate
Kerr Drug and UNC Eshelman School of Pharmacy collaborate in study of personaliz …
Raleigh, NC- March, 2012- Individually tailored drug regimens based on pharmacogenetic testing are increasingly being used to improve response rates and decrease adverse events. Kerr Drug and UNC Eshelman School of Pharmacy at the University of North Carolina Chapel Hill will be exploring the feasibility of a pharmacogenetic program for PLAVIX®(clopidogrel bisulfate), an antiplatelet agent (blood thinner). The study will investigate and evaluate the implementation of a pharmacogenetic
Antithrombotic drug market will rise to 24.4 billion dollars in 2015 visiongain …
Visiongain predicts that the overall world antithrombotic and anticoagulant drug market will reach 24.4 billion dollars in 2015. That forecast appears in Antithrombotic/Anticoagulant Drugs: World Market 2012-2022, published in January 2012. The new study assesses drugs to treat abnormal blood clotting in human beings. It predicts that the industry and market for blood thinners will soon recover from the patent expiries of two leading drugs, Plavix and Lovenox. The overall world